Our team

David served as Chairman of Norfolk and Norwich University Hospitals NHS Foundation Trust from 2002-2012 before becoming Chairman of the Care Quality Commission. In December 2016, he was appointed as Parliamentary Under Secretary of State at the Department of Business, Energy & Industrial Strategy, with specific responsibility for developing industrial strategy. He stepped down from this role in October 2017 to become Chairman of University College London Hospitals and subsequently became Chairman of NHS England and a member of the UK Life Sciences Council from November 2018 to March 2022. He continues to advise the government on Life Sciences and is an advisor to Healthcare UK, providing strategic input into the Department of International Trade's healthcare international exports work.

Our CEO and co-founder is the original designer and creator of the Oricol™ device. Hugo is passionate about discovery, innovation and commercial conversion, having enjoyed a diverse career including scientific education (retail), healthcare (delivery), and primary care investigative and diagnostic solutions across an evolving ongoing range of fields within the science and healthcare sector.

Shane Hall FCA, qualified with BDO, before going on to lead the BDO Corporate Finance division in Northern Ireland across with a 20 year professional services career. In this role he became a key advisor to many of Ireland's leading businesses, across a spectrum of sectors, including Biotech (covering private, listed and private equity backed ownerships).

His specialisms also include Equity Fund raises, M&A. Due diligence, Debt Advisory and Finanial Modelling.

Rupert Lywood is an original founder of Origin Sciences and provided the company’s early finance. A chartered accountant with specialities in structured finance and venture capital, he has spent the past 40 years founding and building businesses in the energy, information, finance, medical and media sectors. As a key early backer, Rupert’s support was instrumental in establishing Origin Sciences, and he remains actively involved in guiding its growth.

Lee, a mathematician by training, qualified as a chartered accountant in 2006 and became a partner in 2008, later leading the sale of his firm to Crowe in 2011. He joined Wilson Wright in 2012, advising leading UK entrepreneurs and family offices. In 2015, while remaining a senior partner, he co-founded Polymateria, now a global leader in biodegradable polyolefin plastics. Since then, he has founded and invested in several businesses. In 2024, Lee led the merger of Wilson Wright and BKL into a top-30 UK accountancy firm with PE backing from CBPE. Today, he invests alongside long-term family office partners, helping portfolio companies achieve their potential.

Our CEO and co-founder is the original designer and creator of the Oricol™ device. Hugo is passionate about discovery, innovation and commercial conversion, having enjoyed a diverse career including scientific education (retail), healthcare (delivery), and primary care investigative and diagnostic solutions across an evolving ongoing range of fields within the science and healthcare sector.

Shane Hall FCA, qualified with BDO, before going on to lead the BDO Corporate Finance division in Northern Ireland across with a 20 year professional services career. In this role he became a key advisor to many of Ireland's leading businesses, across a spectrum of sectors, including Biotech (covering private, listed and private equity backed ownerships).

His specialisms also include Equity Fund raises, M&A. Due diligence, Debt Advisory and Finanial Modelling.

Our Chief Scientific Officer, an Immunologist by training, is an expert in adaptive immunity, nonself recognition and immuno-oncology. Prior to joining Origin, Daniel led the development of epigenetic screening tools in the diagnostic industry for the United Kingdom Accreditation Service. Daniel was previously the CSO and Laboratory Director of Excalibur Diagnostics. Daniel holds a PhD from the University of Cambridge and was a Fellow at the Technical University of Munich.

Andrew Page PhD, Visiting Professor at UEA, formerly held senior roles at Theiagen Genomics, the Quadram Institute, and the Sanger Institute, and is renowned for his open-source contributions in microbial genomics, bioinformatics and computer science. He has over 150 publications including in Nature, Science and Lancet. Provides expert advise on genomics to the UK Government, such as on managing the COVID-19 in care homes (Scientific Advisory Group for Emergencies) and food safety (Food Standards Agency).

Our Chief Medical Officer is also a Consultant Colorectal & General Surgeon based at the Royal Devon & Exeter Hospital. Ian is a leading UK expert in complex colorectal disease, locally advanced and recurrent bowel cancer and abdominal wall reconstruction. He has an extensive research portfolio and leads the Exeter Surgical Health Services Research Unit (HESRU). Outside of clinical work he is Honorary President of Colostomy UK and front row for Team Colostomy UK.

Jamie is a strategic business and operational professional with over 25 years in the medical device, life science & pharma sectors where he’s gained extensive experience of ISO9001/13485, MDSAP & GMP manufacturing with a focus on the development and manufacture of autoimmune and Infectious disease tests as well as new novel technologies.

He has a passion for innovative technology that can transform healthcare & improve patient wellbeing.

Jamie has worked senior roles with responsibility for manufacturing operations, supply chain, quality assurance, regulatory, projects and technical development as well as facilities, EHS and ICT.

Mike is a British oncologist with more than 25 years' experience as a hospital physician. From 1999 to 2013 Mike was appointed as the first National Cancer Director at the Department of Health. He led the development and implementation of the NHS Cancer Plan in 2000, the Cancer Reform Strategy in 2008 and Improving Outcomes: A strategy for cancer in 2011.

Sir Mike led two major reviews for NHS England. A review of adult screening services (2019) and a review of diagnostic services (2020) recommending a major expansion of diagnostic capacity and a new model of service delivery. He is currently working with NHS England to help implement his report and is a trustee of Cancer Research UK. In April 2022 he was appointed as Chair of the UK National Screening Committee. In 2024 he conducted a review of the Single Assessment Framework and its implementation for CQC, which he has since been appointed as its Chair.

Bruce Campbell chaired the NICE Interventional Procedures and Medical Technologies Advisory Committees - 2002-15 and 2009-15 respectively; and he chaired the Therapeutic Procedures Panel of the Health Technology Assessment Programme 2000-8. He was a Non-Executive Director of the MHRA 2015-21. He is a vascular consultant in Exeter and has published extensively on clinical topics, and on health technology assessment.